Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Preview: India's Sun Pharma set for strong Q4 domestic performance

** Shares of Sun Pharma SUN.NS down 0.7% to 1,876.9 rupees ahead of its quarterly earnings; Nifty pharma .NIPHARM down 0.6%

** Analysts, on average expect drugmaker to post 31.3% rise in Q4 net profit at 28.22 billion rupees ($293.8 million) - LSEG-compiled data

** Jefferies projects 14% year-over-year growth in domestic business, driven by strong adoption of chronic therapies

** Brokerage warns of potential sequential decline in U.S. sales due to lower generic Revlimid revenues

** HSBC anticipates a strong quarter, supported by India operations and innovative medicines segment; expects SUN to post mid-single digit to mid-teens YoY growth in India sales but flags possible sequential decline in innovative medicines

** Stock rated as "Buy" on average by 31 analysts; median PT at 1,990 rupees - data compiled by LSEG

** YTD, stock up 9.7% vs Nifty pharma's rise of 8.8%

($1 = 96.0425 Indian rupees)

 (Reporting by Mridula Kumar in Bengaluru)

 ((Mridula.Kumar@thomsonreuters.com;))

Recent news on Sun Pharmaceutical Industries

See all news